Clinical Trial Update: Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients [Phase 2]

View source ↗

Summary

This entry provides an update on a phase 2 trial of irinotecan, TAS-102, and bevacizumab as third-line or beyond therapy for metastatic colorectal cancer, with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING